Teriflunomide*
-
API Product :
Teriflunomide*
-
CEP :
-
-
WCC :
?
-
Therapeutic Use :
Immunostimulating Agents; Other CNS Drugs
-
Originator :
Sanofi-Aventis
-
CAS No. :
163451-81-8
-
Trade Name. :
AUBAGIO
-
Molecular Weight :
270.207 g/mol
-
Molecular Formula :
C12H9F3N2O2
Application
Teriflunomide affects the immune system and reduces swelling and inflammation in the nervous system. Teriflunomide is used to reduce flare-ups in people with relapsing multiple sclerosis (MS). Teriflunomide is not a cure for MS. Teriflunomide may also be used for purposes not listed in this medication guide.
General Description
Teriflunomide (trade name Aubagio, marketed by Sanofi) is the active metabolite of leflunomide.[1] Teriflunomide was investigated in the Phase III clinical trialTEMSO as a medication for multiple sclerosis (MS). The study was completed in July 2010.[2] 2-year results were positive.[3] However, the subsequent TENERE head-to-head comparison trial reported that "although permanent discontinuations [of therapy] were substantially less common among MS patients who received teriflunomide compared with interferon beta-1a, relapses were more common with teriflunomide.